There are currently 40 active clinical trials seeking participants for Solid Tumors research studies. The states with the highest number of trials for Solid Tumors participants are Texas, California, New York and Florida.
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors
Recruiting
Background: Blood, tissue, and tumor cells contain genes. Genes are made up of DNA. DNA is the instruction book for each cell. In some people with cancer, the genes that might have slowed the growth of their tumor were turned off. Researchers want to see if a new drug can turn the genes back on and slow the tumor growth. The drug is called Aza-TdC. Objective: To test the safety of Aza-TdC, and to find out the dose of this drug that can be safely given to humans. Eligibility: People ages 18... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
05/15/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Neoplasms, Solid Tumors
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Recruiting
The purpose of this study is to evaluate the long-term safety and efficacy of pembrolizumab (MK-3475) in participants from previous Merck pembrolizumab-based parent studies who transition into this extension study. This study will consist of three phases: 1) First Course Phase, 2) Survival Follow-up Phase or 3) Second Course Phase. Each participant will transition to this extension study in one of the following three phases, depending on the study phase they were in at the completion of the par... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/14/2025
Locations: Arizona Cancer Center at UMC North ( Site 0018), Tucson, Arizona +662 locations
Conditions: Solid Tumors, Hematologic Malignancies
Study of GS-9911 With or Without Antibody Treatment for Adults With Solid Tumors
Recruiting
The main goal of this first in human (FIH) study is to learn about the safety and dosing of GS-9911 when given alone or in combination with an anti-programmed cell death protein 1 (PD-1) monoclonal antibody in participants with advanced solid tumors. The primary objectives of this study are to: * Assess the safety and tolerability of GS-9911 as monotherapy and in combination with an anti-PD-1 monoclonal antibody in participants with advanced solid tumors * Identify the maximum tolerated dose (... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/13/2025
Locations: Smilow Cancer Hospital Phase 1 Unit, New Haven, Connecticut +5 locations
Conditions: Solid Tumors
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
Recruiting
The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with locally advanced or metastatic solid tumors, or recurrent or progressive primary central nervous system (CNS) tumors harboring BRAF fusions, or in participants with rare BRAF V600-mutated solid tumors, melanoma, thyroid, or recurrent primary CNS tumors.
Gender:
ALL
Ages:
10 years and above
Trial Updated:
05/13/2025
Locations: UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California +55 locations
Conditions: Cancer Harboring BRAF Alterations, HGG, LGG, Solid Tumors, Melanoma BRAF V600E/K Mutated, Thyroid Cancer
Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
Recruiting
TAPISTRY is a Phase II, global, multicenter, open-label, multi-cohort study designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or in rational, specified combinations in participants with unresectable, locally advanced or metastatic solid tumors determined to harbor specific oncogenic genomic alterations or who are tumor mutational burden (TMB)-high as identified by a validated next-generation sequencing (NGS) assay. Participants with solid tumors... Read More
Gender:
ALL
Ages:
All
Trial Updated:
05/12/2025
Locations: Southern Cancer Center, Daphne, Alabama +162 locations
Conditions: Solid Tumors
Combination Nilotinib and Paclitaxel in Adults With Relapsed Solid Tumors
Recruiting
Background: - Researchers want to find better ways to treat cancer. One drug that treats cancer is paclitaxel. Sometimes proteins block that drug from working. Researchers want to see if another drug, nilotinib, helps paclitaxel work better. Objective: - To test the safety of nilotinib plus paclitaxel and find out what doses of the drugs can be given safely to people. Eligibility: - Adults at least 18 years old with advanced cancer that has progressed after receiving standard treatment, or... Read More
Gender:
ALL
Ages:
Between 12 years and 120 years
Trial Updated:
05/09/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Solid Tumors
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Recruiting
This study is conducted to determine the safety and tolerability of INCB161734 as a single agent or in combination with other anticancer therapies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/08/2025
Locations: Mayo Clinic Hospital, Phoenix, Arizona +31 locations
Conditions: Solid Tumors
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
Recruiting
The PROCEADE PanTumor study aims to investigate M9140 in multiple tumor types which express carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) and it is therefore designed as a matrix study. This study aims to assess the antitumor activity, tolerability, safety, and pharmacokinetics (PK) of M9140 as monotherapy or in combination treatments in adult participants with locally advanced/metastatic CEACAM5 expressing tumors. There will be 3 substudies under this Master Protocol that... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/05/2025
Locations: NEXT Virginia, Fairfax, Virginia +3 locations
Conditions: Solid Tumors, Gastric Cancer, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma (PDAC)
First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors
Recruiting
This 2-part study will evaluate safety, tolerability, and clinical efficacy of DS-2243a as a treatment for participants with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/02/2025
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts +1 locations
Conditions: Solid Tumors, Sarcoma
Screening Study for Participants With Malignant Tumors
Recruiting
The study objective is to determine the biomarker status of a participant's tumor tissue and use that status to determine eligibility for a linked Roche clinical trial.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/02/2025
Locations: Arizona Oncology Associates, PC - HOPE, Tucson, Arizona +154 locations
Conditions: Solid Tumors
QTX3034 in Patients With KRAS G12D Mutation
Recruiting
Phase 1 study to determine the safety and tolerability of QTX3034 as a single agent or in combination with cetuximab.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/01/2025
Locations: UCLA Hematology/Oncology, Los Angeles, California +13 locations
Conditions: Solid Tumors
A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
Recruiting
To evaluate the safety, tolerability, and DLTs and determine the MTD and/or RDE(s) of INCA33890 in participants with select advanced or metastatic solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/01/2025
Locations: The Angeles Clinic and Research Institute, Los Angeles, California +33 locations
Conditions: Solid Tumors, Advanced Solid Tumors, Metastatic Solid Tumors